The thesis

UiPath sells robotic process automation software into the AI buildout, and the macro engine is active: AI capital expenditure growth names it a direct beneficiary. The financials carry weight: revenue grew 13.4 percent year over year, gross margin is 82.5 percent, net margin is 21.0 percent, and the stock trades at 19.2 times earnings. Yet the conviction signal is dormant at 12 out of 100, and analysts sit at HOLD. The tension is the point: a profitable, direct AI beneficiary is being priced as if the story were over.

Why now

Management held full-year 2027 revenue guidance at $1.789 billion on a confident tone, guiding Q3 revenue to $440 million to $445 million. Chip supply stays tight through 2030 per Dell, keeping AI capex, and thus automation budgets, committed while UiPath trades at under 20 times earnings.

What to watch

Watch whether Q3 2027 revenue lands at the top of the $440 million to $445 million range and ARR approaches $1.997 billion. Watch the conviction score: a move off 12 would signal capital rediscovering the name, while flatlining through two quarters confirms the dormant read.

Key risks

Software spending is one of the first budgets cut when the economy tightens, andUiPath's growth rate of 13.4 percent leaves little cushion if that happens. A 19.2 times multiple on a净21 percent net margin looks cheap only until growth decelerates. The dormant conviction score also means no capital is currently chasing the name, so the thesis has no momentum behind it.

Theme exposure